Related Experiment Videos
Deciphering the interplay between SGLT2 inhibition, CCL4, and angina pectoris: A Mendelian randomization study
Yujia Zhang1, Yukai Zhao1, Zheng Dong1
1The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province, China.
Medicine
|July 31, 2026
Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors may reduce angina risk by influencing inflammation. This study suggests SGLT2 inhibition impacts C-C motif chemokine ligand 4 (CCL4), a factor linked to angina, indicating a complex protective pathway.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Genetics
Background:
- Angina pectoris, a symptom of coronary artery disease, is linked to inflammation.
- The anti-inflammatory mechanisms of SGLT2 inhibitors are not fully understood.
- C-C motif chemokine ligand 4 (CCL4) is an inflammatory cytokine potentially involved.
Purpose of the Study:
- To investigate if SGLT2 inhibition reduces angina risk through modulation of inflammatory cytokines, particularly CCL4.
- To explore the relationship between SGLT2 inhibition, CCL4, and angina using Mendelian Randomization.
Main Methods:
- A two-sample Mendelian Randomization approach was used.
- Genetic instruments were derived from SLC5A2 eQTLs and HbA1c-associated SNPs.
- GWAS summary statistics for CCL4 and other cytokines were analyzed using inverse variance weighting.
Main Results:
- SGLT2 inhibition was significantly associated with reduced angina risk (OR=0.28, P=0.007).
- CCL4 was the only cytokine linked to both SGLT2 inhibition and angina.
- SGLT2 inhibition positively correlated with CCL4 levels (β=1.14, P=0.006), while CCL4 increased angina risk (OR=1.07, P=0.022).
Conclusions:
- SGLT2 inhibition may offer protective effects against angina pectoris.
- A complex inflammatory pathway involving CCL4 may mediate these effects.
- Further research is needed to elucidate the intricate relationship between SGLT2, inflammation, and cardiovascular outcomes.